UnmeshShah Ph.D.

Dr. Unmesh Shah focuses his practice on obtaining and defending patents for clients in the pharmaceutical, chemical, and biotechnology fields. A substantial part of Unmesh's practice includes conducting due diligence evaluations and providing freedom-to-operate, patentability, infringement, and validity opinions. Unmesh also advises clients with matters relating to patent term extension (PTE) and Orange Book listings.

Unmesh has significant experience in developing, managing, and evaluating global patent portfolios related to diverse technologies, including small-molecule pharmaceuticals, peptides, macromolecules, antibody-drug conjugates (ADCs), immunotherapy, mRNA-lipid nanoparticles, polymorphs, drug formulations, dosing regimens, chemical syntheses and purifications, ocular inserts, packaging, and drug repurposing. Unmesh also advises clients on patent life-cycle management strategies and regulatory extension opportunities.

Unmesh's practice also includes Hatch-Waxman litigations and inter partes review (IPR) proceedings, where he is involved with analyzing paragraph IV letters, conducting inventor interviews, retaining and interacting with subject matter experts, drafting infringement and validity contentions, and preparing experts for depositions and trial.

Prior to joining Jones Day, Unmesh worked for nearly 15 years as a medicinal chemist in the drug discovery group at Merck and Schering-Plough, and he was involved with various therapies, including CNS disorders, CV diseases, metabolic disorders, and infectious diseases. Unmesh's efforts in these areas led to candidates that were advanced to clinical trials.

Unmesh holds a Ph.D. in organic chemistry. His doctoral research involved total synthesis of natural products. He is an inventor on several patents and has authored multiple peer-reviewed articles, including review articles and book chapters. Unmesh has also given oral and poster presentations at national meetings.